CRYOCRATE, LLC

Establishment of a First-in-Class Biocompatible and Efficient Cryopreservation Technology Platform for the Next Generation of Cell-Based Therapeutics in Regenerative Medicine and Drug Discovery

CRYOCRATE, LLC is a business in nih office of the director based in COLUMBIA, MO, founded in 2012.

Profile

SUMMARY
Previous support from NIH SBIR and Coulter Foundation awards allowed the CryoCrate team to develop a first-
in-class biocompatible cryopreservation medium product, trademarked as OdinSol®, that provides enabling and
efficient options for biobanking urgently needed for the development and implementation of cell-based
therapeutics and tissue engineering in personalized medicine.
The OdinSol® technology removes the need for any toxic cell permeating cryoprotectant used in nearly all
existing cryopreservation methods, secures long-term storage in regular -80oC deep freezers, and significantly
improves the cryopreservation efficiency for cell-based therapeutic materials (e.g., iPSC-derived cells or tissues).
Based on our former experience in FDA 510(k) submission, in this project, we organized the collaboration with
our regulatory consultant (Cardinal Health), contract manufacturing organizations (Bryllan), contract research
organization (WuXi AppTec), academic co-inventor (University of Missouri – Kansas City Vision Research
Center), to achieve the following milestones:
I. The production of OdinSol® meets GMP qualifications and biocompatibility assessment shows
compliance with FDA guidance for 510(k) submission as a storage device for transplantable tissues;
II. The in vitro and in vivo evaluation of safety and efficacy demonstrates the OdinSol® technology to be
superior

Within the nih office of the director space, the company focuses on its core offering rather than a broad product line.

The business is associated with COLUMBIA, MO.

It is recorded at the SBIR/STTR stage.

Its team size is recorded as 1-10 employees.

It has disclosed roughly $922K in funding.

Website: cryocrate.com